A5016658618- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Molecular Biology Techniques and Applications
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Reconstructive Facial Surgery Techniques
- Advances in Oncology and Radiotherapy
- Oral and Maxillofacial Pathology
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Nasal Surgery and Airway Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Head and Neck Surgical Oncology
Massachusetts Eye and Ear Infirmary
2022-2024
Harvard University
2024
Massachusetts General Hospital
2024
Abstract Objectives In this feasibility study, we explored the combined use of circulating tumor human papillomavirus (HPV) DNA (ctHPVDNA) and HPV serology as diagnostic tests for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Methods Among patients with research-banked serum or plasma at diagnosis, IgG antibodies to oncoproteins from types 16, 18, 31, 33, 35, 45, 52, 58 were detected multiplex serology. Positivity 16 was defined based on detection combinations anti-E6, E1,...
Abstract Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed accurate MRD at clinically-relevant timepoints. Ultrasensitive immediately after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics poorly understood. Experimental Design We applied MAESTRO, whole-genome, tumor-informed, mutation-enrichment sequencing assay, pooled...
Abstract Background Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive cancer with a median overall survival of only 12 months. Existing biomarkers have limited ability to predict treatment response or survival, exposing many patients the potential toxicity without certain clinical benefit. Circulating tumor DNA (ctDNA) has emerged as non-invasive, real-time biomarker that could address these challenges. Methods We analyzed 137 plasma samples from 16 R/M...
Abstract Background HPV-associated oropharyngeal cancer (HPV+OPSCC) is the most common in United States yet unlike cervical lacks a screening test. HPV+OPSCCs are presumed to start developing 10-15 years prior clinical diagnosis. Circulating tumor HPV DNA (ctHPVDNA) sensitive and specific biomarker for HPV+OPSCC. Taken together, blood-based HPV+OPSCC may be feasible Methods We developed an whole genome sequencing assay, HPV-DeepSeek, with 99% sensitivity specificity at 28 plasma samples from...
This prospective observational study examines if circulating tumor human papillomavirus DNA can be used as an accurate measure of disease status at the time diagnosis, throughout treatment, and during monitoring in papillomavirus-associated sinonasal nasopharyngeal squamous cell carcinomas.
Abstract Background Human papillomavirus‐associated head and neck squamous cell carcinoma (HPV + HNSCC) occurs in the oropharynx OPSCC), sinonasal cavity SNSCC), nasopharynx NPC). Circulating tumor HPV DNA (ctHPVDNA) is an accurate tool for diagnosis, treatment monitoring, recurrence detection. An emerging challenge with ctHPVDNA that ~7.4% of HNSCC patients develop synchronous or metachronous HPV+ primaries, which could confound monitoring. Methods We describe a 65‐year‐old patient T2N1M0...
6051 Background: Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) yet, response rates are poor. Currently there no real-time, non-invasive biomarkers treatment response. Circulating tumor DNA (ctDNA) has shown promising results as a prediction tool in several solid malignancies. In this retrospective study we applied tumor-informed next-generation sequencing liquid biopsy assay (RaDaR, NeoGenomics...
Abstract Introduction: Circulating tumor (ct)DNA approaches are revolutionizing cancer diagnostic and monitoring approaches. In HPV-associated oropharyngeal (HPV+OPSCC), droplet digital PCR(ddPCR)-based detection of ctHPVDNA has gained significant attention but only demonstrates ~90% sensitivity at time diagnosis critically, performs poorly in the minimal residual disease setting, is unable to provide additional prognostic information. For example, our group recently demonstrated strong...
Abstract Introduction HPV-associated head and neck squamous cell carcinomas (HPV+HNSCC) release circulating tumor DNA (ctDNA), including ctHPVDNA, into the blood, which is detectable at time of diagnosis in nearly all patients with HPV+HNSCC using droplet digital PCR (ddPCR)-based approaches. We have previously demonstrated proof principle that these approaches, ctHPVDNA a minority up to 3 years prior diagnosis, suggesting may be reliably detected many clinical detection when more sensitive...
Abstract Background Circulating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid types. Most studies evaluating the utility ctDNA have focused on time points weeks to months after surgery, which for many cancer types, is significantly later than decision-making adjuvant treatment. In this systematic review, we summarize state literature feasibility using a in immediate postoperative period. Methods We performed review early kinetics,...
The auricular composite graft consists of a free tissue containing part the cartilage attached to its overlying skin. survival depends primarily on size, and diameter 1- 2 cm has been previously reported as critical cut-off size. is reliable option for reconstruction skin defects nasal sidewall ala, rates can be enhanced with utilization specific surgical techniques. These include increasing contact surface de-epithelization/ perichondrial underlay in bed, injection autologous platelet-rich...